Edition:
India

Infinity Pharmaceuticals Inc (INFI.OQ)

INFI.OQ on NASDAQ Stock Exchange Global Select Market

2.24USD
8:04pm IST
Change (% chg)

$0.08 (+3.70%)
Prev Close
$2.16
Open
$2.18
Day's High
$2.24
Day's Low
$2.16
Volume
7,327
Avg. Vol
151,405
52-wk High
$3.75
52-wk Low
$0.93

Latest Key Developments (Source: Significant Developments)

Infinity Pharma Qtrly Diluted Loss Per Common Share $0.14​
Friday, 16 Mar 2018 

March 15 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS PROVIDES COMPANY UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS NET LOSS FOR 2018 TO RANGE FROM $35 MILLION TO $45 MILLION​.INFINITY - EXPECTS TO END 2018 WITH A YEAR-END CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES BALANCE RANGING FROM $15 MILLION TO $25 MILLION​.INFINITY PHARMACEUTICALS INC - QTRLY ‍BASIC AND DILUTED LOSS PER COMMON SHARE $ 0.14​.  Full Article

Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS NET LOSS FOR 2018 TO RANGE FROM $40 MILLION TO $50 MILLION​.INFINITY PROVIDES UPDATE ON IPI-549 PHASE 1/1B STUDY, 2018 GOALS AND FINANCIAL GUIDANCE.INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS TO END 2018 WITH A YEAR-END CASH AND INVESTMENTS BALANCE RANGING FROM $10 MILLION TO $20 MILLION​.INFINITY PHARMACEUTICALS INC - EXPECTS TO END 2018 WITH A YEAR-END CASH AND INVESTMENTS BALANCE RANGING FROM $10 MILLION TO $20 MILLION.INFINITY PHARMACEUTICALS INC - ‍INFINITY ENDED 2017 WITH APPROXIMATELY $57.6 MILLION IN CASH AND INVESTMENTS​.  Full Article

Infinity Q3 loss per share $0.14
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Infinity Pharmaceuticals Inc ::Infinity provides company update and reports third quarter 2017 financial results.Q3 loss per share $0.14.Q3 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.Q3 revenue $6.0 million.Q3 revenue view $14.7 million -- Thomson Reuters I/B/E/S.Infinity Pharmaceuticals Inc - ‍infinity expects net loss for 2017 to range from $40 million to $50 million​.Infinity Pharmaceuticals - ‍expects to end 2017 with a cash, cash equivalents and available-for-sale securities balance ranging from $40 million to $50 million​.  Full Article

Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration
Monday, 25 Sep 2017 

Sept 25 (Reuters) - Bristol-Myers Squibb Co :Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration evaluating ipi-549 in combination with Opdivo (nivolumab).Infinity Pharmaceuticals Inc - ‍combination dose-escalation is also ongoing, and combination expansion is expected to begin in second half of 2017​.Infinity Pharmaceuticals Inc - ‍patient enrollment is complete in monotherapy dose-escalation, and monotherapy expansion is ongoing​.Infinity Pharmaceuticals- deal expands Phase 1/1b study to include patients with triple negative breast cancer who havent been previously exposed to anti-PD-1/anti-PD-l1 therapy​.  Full Article

Infinity Q2 loss per share $0.34
Friday, 4 Aug 2017 

Aug 3 (Reuters) - Infinity Pharmaceuticals Inc ::Infinity provides company update and reports second quarter 2017 financial results.Q2 loss per share $0.34.Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Infinity Pharmaceuticals Inc - ‍expects net loss for 2017 to range from $40 million to $50 million​.Infinity Pharmaceuticals- ‍expects existing cash,cash equivalents at june 30, 2017, will be adequate to satisfy company's capital needs into q1 of 2019​.  Full Article

Infinity amends PI3K-Delta,Gamma Agreement with Takeda Oncology
Thursday, 27 Jul 2017 

July 27 (Reuters) - Infinity Pharmaceuticals Inc ::Infinity amends PI3K-Delta,Gamma Agreement with Takeda Oncology.Co says it has amended its license agreement with Takeda Oncology for IPI-549.Co will no longer have obligation to pay Takeda on worldwide net sales of selective inhibitors of PI3K-Gamma.Co remains obligated to pay development, regulatory and commercial milestones to Takeda for IPI-549.  Full Article

Infinity reports Q1 loss per share $0.21
Wednesday, 10 May 2017 

May 9 (Reuters) - Infinity Pharmaceuticals Inc :Infinity provides company update and reports first quarter 2017 financial results.Q1 loss per share $0.21.Q1 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Infinity Pharmaceuticals Inc - Infinity expects net loss for 2017 to range from $40 million to $50 million..  Full Article

Infinity expects net loss for 2017 to range from $40 mln-$50 mln
Wednesday, 15 Mar 2017 

Infinity Pharmaceuticals Inc : Infinity provides company update and reports fourth quarter 2016 financial results . Infinity Pharmaceuticals Inc- expects net loss for 2017 to range from $40 million to $50 million . Infinity Pharmaceuticals- expects to end 2017 with year-end cash, cash equivalents, available-for-sale securities balance ranging from $40 million-$50 million .Infinity Pharma- expects existing cash, cash equivalents, available-for-sale securities at Dec. 31, 2016, adequate to satisfy capital needs into Q1 2019.  Full Article

Infinity expects net loss for 2017 in the range of $40 mln to $50 mln
Monday, 9 Jan 2017 

Infinity Pharmaceuticals Inc : Infinity provides 2017 goals and financial guidance . Infinity Pharmaceuticals Inc - expects to end 2017 with a year-end cash and investments balance ranging from $40 million to $50 million . Infinity Pharmaceuticals Inc - expects net loss for 2017 to range from $40 million to $50 million. . Infinity Pharmaceuticals - updated cash runway expectation assumes receiving $6.0 million milestone payment from verastem for positive duo study results .Infinity Pharmaceuticals sees existing cash, cash equivalents, available-for-sale securities at Dec 31 2016 to be adequate to satisfy capital needs into Q1 2019.  Full Article

Infinity Pharma Q2 earnings per share $1.05
Wednesday, 10 Aug 2016 

Infinity Pharmaceuticals Inc : Q2 earnings per share $1.05 . Q2 revenue $9.5 million . Infinity provides company update and reports second quarter 2016 financial results . Q2 earnings per share view $-0.89 -- Thomson Reuters I/B/E/S . Q2 revenue view $13.9 million -- Thomson Reuters I/B/E/S . Continuing to explore a broad range of strategic options for duvelisib, including a potential sale of program . "in parallel, company continues to advance key value drivers for duvelisib" . Infinity is also proceeding with its planned development of ipi-549 in multiple solid tumors .Duo study of duvelisib compared to ofatumumab in 319 patients with relapsed or refractory cll, will proceed to final analysis.  Full Article

BRIEF-BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10

* BVF PARTNERS LP REPORTS 21.7 PCT STAKE IN INFINITY PHARMACEUTICALS INC AS OF APRIL 10 - SEC FILING